Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales and various cardiometabolic risk scales in 219.477 Spanish workers

• Emilio Martínez-Almoyna Rifá ^[1] ; Pilar Tomás-Gil ^[1] ; Josep Lluis Coll Villalonga ^[1] ; José Ignacio Ramírez-Manent ^{[1] [2]} ; Pau Martí-Lliteras ^[1] ; Ángel Arturo López-González ^[1]
  1. [1] Universitat de les Illes Balears

     Universitat de les Illes Balears

     Palma de Mallorca, España

     
  2. [2] Mallorca Primary Care
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 38, Nº. 5, 2023, págs. 138-145
• Idioma: inglés
• DOI: 10.3306/AJHS.2023.38.05.138
• Títulos paralelos:
  • Relación entre escalas de riesgo de higado graso no alcohólico y fibrosis hepática con diversas escalas de riesgo cardiometabólico en 219.477 Trabajadores españoles
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Introducción: La enfermedad del hígado graso no alcohólico (EHGNA) es la principal causa de hepatopatía crónica en occidente, pudiendo cursar en estadios tardíos con cirrosis por lo que se prevé que se convierta en la indicación más frecuente para el trasplante de hígado para la próxima década.

    Material y métodos: Estudio descriptivo y transversal en 219.477 trabajadores españoles en los que se determina el riesgo de presentar EHGNA y fibrosis hepática con 7 escalas diferentes y el riesgo cardiometabólico establecido a partir de los índices aterogénicos, síndrome metabólico, dislipemia aterogénica, triada lipídica y riesgo de prediabetes aplicando la escala PRISQ.

    Resultados: Se aprecia un incremento en los valores medios y en la prevalencia de valores de alto riesgo de todas las escalas de EHGNA y fibrosis hepática en las personas con alto riesgo cardiometabólico frente a las personas con menor riesgo.

    Conclusiones: Existe una buena relación entre las escalas de riesgo de EHGNA y fibrosis hepática y las escalas de riesgo cardiometabólico analizadas.

  • English

    Introduction: Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease in the West, and in late stages it can lead to cirrhosis, which is expected to become the most frequent indication for liver transplantation in the next decade.

    Material and methods: Descriptive and cross-sectional study in 219.477 Spanish workers in which the risk of presenting NASH and liver fibrosis was determined with 7 different scales and the cardiometabolic risk established from atherogenic indices, metabolic syndrome, atherogenic dyslipidemia, lipid triad and risk of prediabetes applying the PRISQ scale.

    Results: There was an increase in the mean values and in the prevalence of high-risk values of all the NASH and liver fibrosis scales in persons at high cardiometabolic risk compared to those at lower risk.

    Conclusions: There is a good relationship between the NASH and liver fibrosis risk scales and the cardiometabolic risk scales analyzed.

• Referencias bibliográficas
  • Sattar N, Gill JMR, Alazawi W. Improving prevention strategies for cardiometabolic disease. Nat Med. 2020 Mar;26(3):320-325. doi: 10.1038/s41591-020-0786-7.
  • Bedogni G, Gastaldelli A, Foschi FG. Fatty liver, cardiometabolic disease and mortality. Curr Opin Lipidol. 2020 Feb;31(1):27-31. doi: 10.1097/MOL.0000000000000652.
  • Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3.
  • Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2018;24(38):4574-4586....
  • Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar 24;323(12):1175-1183....
  • Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract. 2020 Feb;35(1):72-84....
  • Chung TH, Kim JK, Kim JH, Lee YJ. Fatty Liver Index as a Simple and Useful Predictor for 10-year Cardiovascular Disease Risks Determined by Framingham...
  • Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in...
  • Li L, You W, Ren W. The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. Acta Diabetol. 2017 Oct;54(10):905-911....
  • Wang J, Li P, Jiang Z, Yang Q, Mi Y, Liu Y, et al. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index...
  • Motamed N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, Perumal D, Ashrafi GH, et al. The Ability of the Framingham Steatosis Index (FSI) to...
  • Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Nonalcoholic fatty...
  • Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis...
  • Riutord-Sbert P, Riutord B, Riutord N, Arroyo S, López-González AA, Ramírez-Manent JI. Relationship between healthy habits and sociodemographic...
  • Riutord-Sbert P, Riutord B, Riutord N, Arroyo S, López-González AA, Ramírez-Manent JI. Relationship between physical activity and adherence...
  • Abbas M, Mall R, Errafii K, Lattab A, Ullah E, Bensmail H, et al. Simple risk score to screen for prediabetes: A cross-sectional study from...
  • Deuremberg Riutord-Sbert P, Riutord B, Riutord N, Arroyo S, López-González AA, Ramírez-Manent JI. Influence of physical activity and mediterranean...
  • RFM Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage – A cross-sectional study in American...
  • Busquets-Cortés C, López C, Paublini H, Arroyo Bote S, López-González ÁA, Ramírez-Manent JI. Relationship between Atherogenic Dyslipidaemia...
  • Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C, et al.. Propuestas de clase social neoweberiana y neomarxista...
  • Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Mobasseri M, Naghshi S, Ostadrahimi A. The association of the steatosis severity, NAFLD fibrosis...
  • Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic...
  • Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016 Aug;65(8):1109-23....
  • Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar 24;323(12):1175-1183....
  • Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10....
  • Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016...
  • Stefan N, Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296....
  • Cuthbertson DJ, Koskinen J, Brown E, Magnussen CG, Hutri-Kähönen N, Sabin M, et al. Fatty liver index predicts incident risk of prediabetes,...